This technology involves a series of modified HCT116 colon cancer cell lines in which the BID gene has been completely deleted from both chromosomes using AAV gene targeting. The cells lack all BID expression along with the FADD protein, resulting in robust resistance to apoptosis when exposed to selected anticancer agents. Two extensively characterized clones display these unique features, making them an exceptional model for studying apoptosis pathways and the interplay between intrinsic and extrinsic cell death mechanisms in cancer research.